 |
|
|
| |
Impact of direct acting antiviral market access policy barriers and restrictions for Hepatitis C (HCV) patients: a database analysis of claims from states with and without Medicaid restrictions
|
| |
| |
European Association for the Study of the Liver (EASL) 2024; June 5-8, 2024; Milan, Italy
Nancy Reau1, Krithika Rajagopalan2, Dilip Makhija3, Fatema Turkistani2, Caroline Burk3, Marvin Rock3, and Michelle Martin4
1 Rush University Medical Center, Chicago, IL; 2 Anlitiks, Inc., Dover, MA, United States; 3 Gilead Sciences, Inc., Foster City, California, United States; 4 University of Illinois at Chicago College of Pharmacy, Chicago, IL
|
| |
|
|
|
|
|
